

# Antiarrhythmic drugs

Lec1


Pharmacology 4<sup>th</sup> stage

أ.م.د. اسامة ايوب


## Class II Antiarrhythmic Drugs

- Class II agents are **B-adrenergic antagonists**.
- These drugs diminish Phase 4 depolarization, thus **depressing automaticity, prolonging AV conduction**, and decreasing heart rate and contractility
- In addition,  $\beta$ -blockers prevent life-threatening ventricular arrhythmias following a myocardial infarction

## Class II Antiarrhythmic Drugs

- 
- **Metoprolol is the  $\beta$ -blocker** most widely used in the treatment of cardiac arrhythmias. Compared to nonselective  $\beta$ -blockers, such as propranolol, it **reduces the risk** of bronchospasm.
  - It is extensively metabolized by CYP2D6 and has CNS penetration (**less than** propranolol, but **more than** atenolol)
  - Common adverse effects with  $\beta$ -blockers include **bradycardia, hypotension, and fatigue**

## Class III Antiarrhythmic Drugs

- 
- Class III agents **block potassium channels** and, thus, diminish the outward potassium current during repolarization of cardiac cells.
  - These agents prolong the duration of the action potential without **altering Phase 0** of depolarization or the resting membrane potential.
  - they prolong the effective refractory period. All Class III drugs have the potential to **induce arrhythmias**.

# Amiodarone

- Amiodarone contains **iodine** and is related structurally to thyroxine.
- It has complex effects, showing **Class I, II, III, and IV** actions as well as  $\alpha$ -blocking activity
- Despite its adverse effect profile, amiodarone is thought to be **the least proarrhythmic** of the class I and III antiarrhythmic drugs.



# Amiodarone

- Amiodarone is effective in the treatment of **severe refractory supraventricular** and **ventricular tachyarrhythmias** .
- Despite its side-effect profile, amiodarone is the most **commonly employed** antiarrhythmic.
- **prolonged half-life** of several weeks, full clinical effects may not be achieved until months after initiation of treatment, unless loading doses are employed.





## Adverse effects

- Amiodarone **shows a variety of toxic** effects
  - pulmonary fibrosis,
  - neuropathy,
  - hepatotoxicity,
  - Corneal deposits, optic neuritis,
  - blue-gray skin discoloration, and
  - hypo- or hyperthyroidism.
- Amiodarone is subject to **numerous drug interactions**, since it is metabolized by CYP3A4 and serves as an inhibitor of CYP1A2, CYP2C9, CYP2D6, and P-glycoprotein.



## Dronedarone

- is a **benzofuran amiodarone derivative**, which is less lipophilic, has lower tissue accumulation, and has a shorter serum half-life than amiodarone.
- It **does not have the iodine** moieties that are responsible for thyroid dysfunction associated with amiodarone.
- Currently, dronedarone is used **to maintain sinus rhythm** in atrial fibrillation or flutter, but it is less effective than amiodarone.





# Sotalol

- Sotalol , although a class III antiarrhythmic agent, also has potent **nonselective B-blocker** activity.
- Sotalol blocks a **rapid outward potassium** current, known as the **delayed rectifier**. This blockade **prolongs** both repolarization and duration of the action potential, thus lengthening the effective refractory period.
- suppress **ectopic beats** and to reduce myocardial oxygen demand



# Sotalol

- Sotalol is used for **maintenance of sinus rhythm** in patients with atrial fibrillation, atrial flutter, or refractory paroxysmal supraventricular tachycardia
- The **dosing interval should be extended in patients** with renal disease, since the drug is renally eliminated.
- To reduce the risk of proarrhythmic effects, **sotalol should be initiated in the hospital to monitor QT interval.**





## Dofetilide

- Is a **pure K<sup>+</sup> channel blocker**. It can be used as a first-line antiarrhythmic agent in patients with persistent atrial fibrillation and heart failure or in those with coronary artery disease.
- **Because of the risk of proarrhythmia**, dofetilide initiation is limited to the inpatient setting.



## Ibutilide


- Is a **K<sup>+</sup> channel blocker** that also **activates the inward Na<sup>+</sup> current**
- Ibutilide is the drug of choice for chemical conversion of atrial flutter, but electrical cardioversion has supplanted its use.
- It undergoes extensive first-pass metabolism and is not used orally.
- Initiation is also limited to the inpatient setting due to the risk of arrhythmia.

## Class IV Antiarrhythmic Drugs

- The **nondihydropyridine** Ca<sup>2+</sup> channel blockers verapamil and Diltiazem.
- Although voltage-sensitive Ca<sup>2+</sup> channels occur in many different tissues, **the major effect** of Ca<sup>2+</sup> channel blockers is on **vascular smooth muscle and the heart**.
- In the heart, verapamil and diltiazem bind **only to open depolarized voltage-sensitive channels**, thus decreasing the inward current carried by Ca<sup>2+</sup>.
- These drugs are use dependent in that they **prevent repolarization until the drug dissociates** from the channel, resulting in a decreased rate of phase 4
- They also **slow conduction in tissues** that are dependent on Ca<sup>2+</sup> currents, such as the AV and SA nodes .



**Class IV drugs slow Phase 4 spontaneous depolarization and slow conduction in tissues dependent on calcium currents, such as the AV node.**







## Class IV Antiarrhythmic Drugs

- These agents are **more effective against atrial** than against ventricular arrhythmias.
- They are useful in treating reentrant supraventricular tachycardia and in reducing the ventricular rate in atrial flutter and fibrillation.
- Common adverse effects include
  - **bradycardia,**
  - **hypotension, and**
  - **peripheral edema.**
- Both drugs required dosage adjustments in patients with **hepatic dysfunction.**
- Both agents are subject to many drug interactions as they are **CYP3A4 inhibitors**, as well as substrates and inhibitors of **P-glycoprotein.**

## Other Antiarrhythmic Drugs

### Digoxin

- *Digoxin inhibits the Na<sup>+</sup>/K<sup>+</sup>-ATPase pump,*
- ***shortening** the refractory period in **atrial and ventricular myocardial cells***
- ***prolonging** the effective refractory period and diminishing velocity in the **AV node**.*
- *Digoxin is used to control ventricular response rate **in atrial fibrillation and flutter**; however, sympathetic stimulation easily overcomes the inhibitory effects of *digoxin*.*
- *At toxic concentrations, digoxin causes ectopic ventricular beats that may result in VT and fibrillation*



## Adenosine

- Adenosine is a naturally occurring nucleoside, but at high doses, the **drug decreases conduction velocity, prolongs the refractory period**, and decreases automaticity in the AV node.
- *Adenosine* has an **extremely short duration** of action (approximately 10 to 15 seconds) due to rapid uptake by erythrocytes and endothelial cells.

## Magnesium sulfate

- Magnesium is **necessary for the transport** of  $\text{Na}^+$ ,  $\text{Ca}^{2+}$ , and  $\text{K}^+$  across cell membranes.
- It **slows the rate of SA node impulse** formation and **prolongs conduction time** along the myocardial tissue.
- magnesium is the drug of choice for treating the potentially fatal arrhythmia **torsades de pointes** and digoxin-induced arrhythmias.

